Lack of clinical efficacy of chronic oral physostigmine in Alzheimer's disease

Abstract

Ten patients with mild to severe Alzheimer's disease were treated for up to 10 months with 10 to 15 mg oral physostigmine daily or with placebo, according to a single blind, multiple crossover protocol. No clinically meaningful improvement occurred with physostigmine treatment.